A prescription has two halves and buyers almost always check only one. The clinician must be permitted to prescribe where the patient sits, which is the subject of the state rules article. The pharmacy must separately hold a license from that same state before it may put a package in the mail. That second license has a name in statute after statute — the nonresident pharmacy license — and it is the thing that actually determines who can ship where.
What a nonresident pharmacy is, in the states’ own words
The definitions converge on the same idea from different directions. California: “Any pharmacy located outside this state that is involved in the preparation, dispensing, shipping, mailing, or delivery, in any manner, of controlled substances, dangerous drugs, or dangerous devices into this state shall be considered a nonresident pharmacy,” and “a person shall not act as a nonresident pharmacy unless the person has obtained a license from the board.”[1] Texas states the prohibition rather than the status: a pharmacy located in another state “may not ship, mail, or deliver to this state a prescription drug or device dispensed under a prescription drug order … unless the pharmacy is licensed by the board or is exempt.”[2]
Illinois defines it by the carrier — “a pharmacy that is located in a state, commonwealth, or territory of the United States, other than Illinois, that delivers, dispenses, or distributes, through the United States Postal Service, commercially acceptable parcel delivery service, or other common carrier, to Illinois residents, any substance which requires a prescription”[3] — and New York reaches the internet by name, its nonresident establishment definition adding that such establishments “shall include, but not be limited to, pharmacies that transact business through the use of the internet.”[4]
Louisiana treats the activity as presence: shipping prescription drugs to residents in Louisiana “constitutes doing business in Louisiana.”[5] Michigan requires a license for any pharmacy “whether or not located in this state,” and adds that to do business there an entity providing compounding services must be licensed as a pharmacy or manufacturer.[6] Ohio issues a distinct instrument: a “nonresident license applies to a person whose business operations are located outside this state.”[7]
What the receiving state demands in exchange
The conditions recur to a striking degree, which is the real answer to why a seller ships to 43 states rather than 50: each one is a separate application with separate ongoing duties. A live home-state license comes first. Texas requires “evidence that the applicant holds a pharmacy license, registration, or permit in good standing issued by the state in which the pharmacy is located,” along with the name of the owner and pharmacist-in-charge for service of process, an affidavit that the pharmacist-in-charge has read the applicable laws, and proof of creditworthiness.[2] California requires the nonresident pharmacy to “maintain, at all times, a valid unexpired license, permit, or registration” in its home state and to identify a California-licensed pharmacist working at the out-of-state site to serve as pharmacist-in-charge.[1] Louisiana’s rules go further still: its pharmacist-in-charge must hold an active Louisiana license, hold an active license in the state where the pharmacy sits, and be “present and practicing … no less than 20 hours per week.”[8]
Records come second, and the deadlines are short. Texas requires the ability to produce a dispensing record “not later than 72 hours after the time the board requests the record”; Louisiana’s rules set the same 72-hour window and a two-year retention floor; California and Illinois both require records on their residents to be held so they are readily retrievable from everything else the pharmacy dispenses.[2][8][1][3]
Then a telephone. California, Illinois, New York and Louisiana each require a toll-free line staffed so a patient in that state can reach a pharmacist with access to their records — California and Illinois specifying not less than six days a week and a minimum of 40 hours — and California, Illinois and Louisiana each require that number to appear on the label of the container.[1][3][4][8] That is a consumer-facing obligation hiding in a licensing statute: the bottle is supposed to carry a way to reach a pharmacist.
The gate that is specific to a compounded injection
Four of the statutes quoted here make an inspection part of the bargain, and one singles out exactly the product a GLP-1 buyer receives. Texas requires, with the application, “an inspection report issued … not more than two years before the date the license application is received … by the pharmacy licensing board in the state of the pharmacy’s physical location.” And then it adds a separate rule: “A license may not be issued to a pharmacy that compounds sterile preparations unless the pharmacy has been inspected by the board to ensure the pharmacy meets the safety standards and other requirements.”[2] A compounded semaglutide or tirzepatide vial prepared for injection is a sterile preparation. Under that provision the Texas board’s own inspectors, not the home state’s, are the condition of the license.
California requires the most recent home-state inspection report at registration and reserves the right to inspect the out-of-state site itself, with the pharmacy depositing the board’s estimated costs.[1] Louisiana requires the most recent home-state report plus any FDA or DEA inspection reports, and may inspect “in addition to or in lieu of” the home state’s, recovering its expenses.[5] Michigan requires an out-of-state compounding pharmacy to reimburse the department for the cost of inspecting it.[6] Which category of compounder is being inspected, and under which federal standard, is set out in the 503A and 503B article.
Texas also closes the advertising side of the door: “A pharmacy that is not licensed under this chapter may not advertise the pharmacy’s services in this state.” Its exemption is narrow — the board may excuse a pharmacy that restricts “to isolated transactions” its dispensing to residents of the state[2] — which is the opposite of a subscription.
Federal law does not supply this, and says so
There is no federal pharmacy license. The Drug Supply Chain Security Act does preempt state standards, but only for a category that is not the dispensing pharmacy: from November 27, 2013 no state may set licensure standards for wholesale distributors or third-party logistics providers inconsistent with the federal ones. The same section then preserves everything else — “Nothing in this section shall be construed to preempt State requirements related to the distribution of prescription drugs” outside product tracing and those two categories.[9] FDA describes the division from its own side, stating that states “are primarily responsible for day-to-day oversight over the vast majority of the thousands of compounders in the U.S., most of which do not register with FDA.”[10] Who turns up and what they do is covered in the oversight article.
What licensure rules actually change, and the direction reverses
The cleanest measurement of whether these rules bind concerns the prescriber side rather than the pharmacy side, and its result does not point one way. A quasi-experimental study of a 5% sample of age-qualifying Medicare fee-for-service beneficiaries analyzed 141,199,029 outpatient encounters for 1,682,501 beneficiaries between January 2018 and December 2022, comparing states by whether they joined the Interstate Medical Licensure Compact before the public health emergency and whether they relaxed policy during it. Before the emergency, compact participation was associated with substantially more out-of-state telehealth: adjusted odds ratio 2.24 (95% CI 2.09 to 2.40), with no association for in-state telehealth (aOR 0.98; 95% CI 0.96 to 1.01). During the emergency the sign flipped, to aOR 0.74 (95% CI 0.72 to 0.75) for out-of-state telehealth in compact states and 0.83 (95% CI 0.81 to 0.85) where policy was relaxed, while in-state telehealth rose modestly in both.[11]
The same policy, measured the same way, is associated with a doubling in one period and a quarter-reduction in the next. Once every state had opened its doors, the advantage of having pre-cleared the licensure hurdle disappeared. A license is a gate rather than a demand, and what comes through it depends on what else is open.
What sellers on this site publish about coverage
Across the 286 seller write-ups published here, 169 record a state-coverage statement of some kind and 117 record none. Of the 169, 111 assert complete national coverage — fifty states, all fifty, or fifty-one jurisdictions. 52 state a bounded footprint: a number below fifty, a named list of states, or an explicit exclusion. And 6 say “nationwide” with no list published at all.
Every one of those is a floor rather than a census. The field records what a seller published at the time its write-up was made; a coverage list can change between visits as a registration is granted or lapses, and an empty field can mean the seller published nothing or that the question was not adjudicated. Treat a seller with no recorded statement as unmeasured, not as national.
The interesting group is the smallest. 10 write-ups name a state the seller explicitly does not serve. Across those ten, Mississippi appears 5 times — more than any other state — with Michigan, Arkansas, Louisiana, Alabama, California, Alaska and New Jersey appearing twice each. Ten is far too small a base for a rate, and the pattern is a hypothesis this page cannot test: Mississippi’s own statute could not be retrieved from a primary source, so nothing here is a claim about that state’s rules. What it does establish is narrower and still useful. A seller naming the states it will not serve is telling you more than one asserting all fifty.
How to verify it yourself
The check takes about two minutes once you have a name, and getting the name is the hard part, which is the subject of the vetting article. FDA maintains a directory of board of pharmacy license databases covering 54 jurisdictions and tells consumers what to do with it: “Click on your state to look for your online pharmacy in the state’s board of pharmacy license database. If your online pharmacy is not listed, you should not use that pharmacy.” That page is current as of November 13, 2024.[12]
The state databases are more specific than most people expect. California’s license search offers Non-Resident Sterile Compounding as its own facility license type, distinct from Pharmacy and from Sterile Compounding, and the board states that information on its site “can be accepted as verification of a license”under section 4106 of the Business and Professions Code.[13] Texas publishes a pharmacy search alongside a page verifying an inspector’s association with the board for Class E-S (Non-Resident Sterile Compounding) inspections, cautioning that its data is current as of the previous working day “with the exception of information relating to the existence of disciplinary orders.”[14] Florida runs a verification search whose board selector includes the Board of Pharmacy.[15]
One figure belongs here with its date attached. FDA’s consumer pharmacy pages state that “at any given time, there are roughly 35,000 active online pharmacies, and according to the National Association of Boards of Pharmacy, approximately five percent of those websites comply with U.S. pharmacy laws and practice standards” — on a page current as of September 21, 2020, attributed by FDA to a trade association rather than asserted as its own measurement.[16] It describes online pharmacy websites in general rather than this category of seller, it is six years old, and it is quoted because it is the only published figure of its kind found.
Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed, so a license check is not a quality check either. What it establishes is narrower and real: that a specific, named, inspectable business is answerable to the regulator in the state where the package lands. A seller that will not name the pharmacy has made that check impossible, which is one of the tells in the red-flag article.
What could not be established
No primary-source count of how many states require a nonresident pharmacy license was located, and none is estimated here; the trade association most likely to publish one refused every request made to its site. The Mississippi, Alabama and Arkansas statutes could not be retrieved, which is why no claim about them appears above despite their prominence in sellers’ exclusion lists. And no study was found measuring how often a pharmacy shipping a compounded GLP-1 holds the receiving state’s license. How each figure here was derived is described in the methodology. Nothing on this page is legal advice, and a question about a specific pharmacy or a specific state belongs with that state’s board.